INTRODUCTION
Depression is a prevalent and potentially debilitating condition that is projected to become the second most burdensome disease worldwide by 2030. 1 Antidepressant medication effectively reduces symptom severity and recurrence risk, but nonadherence is common. 2, 3 Although telephone care management is an evidence-based and cost-effective strategy for improving antidepressant medication adherence, 4 its implementation is often not feasible in resource-constrained settings due to high numbers of undertreated patients and limited numbers of trained providers. 5 Mobile health (mHealth) services such as interactive voice response (IVR) telephone calls, smartphone applications, and text messaging may help to address these problems. In IVR calls, patients respond to prerecorded queries using either their telephone keypad or voice recognition technology. We have designed and implemented an mHealth IVR system named BCarePartners,^6 in which patients undergo weekly automated IVR telephone assessments and receive messages regarding their medication adherence and symptom control, and their clinicians are automatically notified of urgent problems such as acute worsening of depression symptoms.
Because many patients attribute their depression to insufficient social support, 7 and those with high-quality support have better outcomes, 8, 9 it may also be beneficial to intensify the self-management support that patients receive from trusted confidants. While their significant others often provide invaluable assistance, these helpers are at high risk for psychological distress. 10 Friends or relatives from outside the household may be willing to assist, but they usually lack effective tools for systematically monitoring patients' moods and encouraging effective self-management. To address these issues, a program was designed that would allow patients to choose an informal support person who automatically receives structured updates about their depression status, along with problem-specific guidance on supporting their self-management. To our knowledge, the CarePartners program is the only patient-centered automated mHealth program that integrates a member of the patient's social support network. We have established that the program has a high rate of engagement, yields valid and reliable clinical information, generates a manageable number of clinician notifications, and responds appropriately to urgent situations when implemented for depression 6 as well as for four other chronic conditions. 11 However, we are unaware of any other telephonic programs incorporating a support person. Therefore, this study tests the hypothesis that patients who choose to include a support person in their mHealth program show better improvement in adherence, symptoms, and function than those who participate in the same program without a support person.
METHODS

Patient Eligibility and Recruitment
Patients. Patients were enrolled between March 2010 and January 2012 from 13 primary care practices. To be eligible, patients had to have had two primary care visits within the previous two years and at least one within the previous 13 months, and either (a) an active depression diagnosis or (b) an antidepressant prescription, together with a billing diagnosis of depression. We excluded patients with a diagnosis of psychotic disorder, bipolar disorder, or dementia. We mailed an introductory letter to potentially eligible patients and then solicited their participation by telephone. Participants provided written informed consent. Given our focus upon medication adherence, we selected for data analysis only patients who were at risk for nonadherence, as indicated by the well-validated Morisky Medication Adherence Scale (MMAS). 12 Higher MMAS scores reflect poorer adherence, and we used a stringent cutoff of >1 to identify baseline risk for nonadherence. The protocol was approved by our institutional review board.
Support Person. At enrollment, patients were offered the option of participating together with a supportive family member or friend. We used the Norbeck Social Support Questionnaire (NSSQ) 13 to facilitate their identification of the most appropriate support person. Support persons were required to be at least 18 years old, have no history of psychosis or cognitive impairment, and agree to receive electronic reports based on information reported during the patient's IVR calls.
Baseline Assessment
Following the informed consent process, patients provided information on their sociodemographic and clinical characteristics. At baseline only, we used the eight-item version of the Patient Health Questionnaire (PHQ-8) 14 to evaluate depression symptom severity. It is identical to the PHQ-9, but without the suicidality item. As noted above, we used the MMAS to assess baseline nonadherence to antidepressants. Health literacy was measured with an abbreviated screen based upon the Test of Functional Health Literacy in Adults, which provides a binary indicator of inadequate health literacy. 15 We estimated number of comorbid chronic conditions based on the self-reported presence of hypertension, cardiovascular disease, hyperlipidemia, stroke, arthritis, chronic lung disease, and low back pain.
Intervention Program
General Program Structure and Processes. The program provided (a) the patient with IVR monitoring of depression symptoms and medication adherence, including tailored information about self-care and when to seek health services; (b) the patient's clinical team with actionable feedback about IVR-reported problems; and (c) the support person with problem-tailored guidance on providing self-management support. Patients were scheduled to receive weekly IVR calls. Each week that an IVR call was scheduled (i.e., Bcall-week^), the system made up to nine call attempts at patient-selected day/time combinations. Call contents were developed by a multidisciplinary team, and calls typically lasted 5-7 min. The program was provided to all patients for at least six months.
IVR-Based Assessments. Patients' symptoms of depression were assessed during each call using the PHQ-9 16 (as opposed to the PHQ-8, 14 which was used only at baseline). We defined remission (a primary outcome) as PHQ-9 total of<5. Acute clinical worsening was defined as a PHQ-9 increase≥7 points since the preceding assessment. If patients reported possible thoughts of self-harm or of Bbeing better off dead,^they were then asked follow-up questions to assess their safety. Adherence to antidepressant medication was assessed during IVR calls by asking: BMany people have difficulty taking their medicine exactly as prescribed by their doctor. How often would you say you took your depression medicine exactly as prescribed this past week?^(on a scale ranging from 1 (Balways^) to 4 (Brarely or never^). We stringently dichotomized adherence as perfect versus less than perfect (another primary outcome), which tends to correct for inflated adherence self-reporting. 2, 17 The IVR system also assessed functional impairment (the third primary outcome) by asking whether the patient had stayed in bed for any entire day during the past week due to mental health problems.
Patient Self-Management Messages. For each major area assessed during the IVR calls, patients heard either a positive acknowledgement message when they reported doing well, or a problem-specific self-management support message when they reported a difficulty. Patients reporting suicidal ideation were advised to discuss this with their physician, and given the number of a 24-hour suicide hotline. Those meeting additional criteria for suicidal risk were also given information on emergency assistance and offered immediate transfer to a suicide hotline.
Clinician Alerts. Clinician alerts were triggered if: (a) the IVR data indicated elevated suicide risk, (b) the PHQ-9 score increased by either≥7 or from<15 to≥15 since the preceding assessment, (c) the patient reported either Brarely or nevert aking their antidepressant as prescribed, or (d) the patient reported reducing or discontinuing their antidepressant without medical supervision.
Support Persons' Reports. Patients' designated support persons were emailed a report after each completed call that summarized the patient's symptoms, impairment level, adherence, and miscellaneous issues. This included detailed suggestions on strategies for supporting the patient's selfmanagement. Further details on the intervention program are available from the authors upon request.
Data Analysis
We analyzed the data using STATA 11.2. 18 Initial descriptive analyses were used to characterize patient participants overall and by groups defined by whether or not the patient participated with a support person. We evaluated group differences in baseline characteristics using Student's t tests for continuous variables and chi-squared tests for categorical variables. Next, the primary analyses were conducted at the level of callweek within patients and included all available data (i.e., no data were imputed). We divided the study timeline into two phases for analysis: acute (weeks 1-6) and maintenance (weeks 7-26). Our primary analyses used multivariable logistic regression to evaluate group differences in the odds of adhering to antidepressant medication, achieving symptom remission (i.e., PHQ-9<5), and having at least one bed day due to depression. We adjusted all models for baseline symptom severity (PHQ-8) and demographic covariates selected through preliminary analysis, and we further adjusted the adherence model for baseline adherence (MMAS). The primary effect of interest was the group X week interaction term, which we followed up within groups. We plotted significant effects across weeks, with locally weighted scatterplot smoothing (LOWESS) 19 to facilitate visual interpretation. We used a p criterion of<0.05 to judge statistical significance after adjusting standard errors for clustering of call-weeks within patients, except for preliminary analyses to identify confounders, for which we used a criterion of p<0.10.
RESULTS
Patient Characteristics
Of the 1,330 patients contacted, we qualified and enrolled 387, of which 221 (57%) met criteria for being at risk for nonadherence and therefore comprised the analytic sample (see Table 1 ). The typical participant was a married white woman with at least some postsecondary education. Participants were 50 years of age on average, with 19% ≥60 years old and approximately half with ≥3 chronic comorbid conditions. Baseline PHQ-8 scores indicated Bmoderate^severity on average, with about one-fourth of patients meeting criteria for either symptom remission or at least Bmoderately severeŝ ymptoms, respectively. Sixty-one percent of patients enrolled with a support person (SP group, n=135), while the remainder enrolled alone (control group, n=86). 
Associations Between Group and IVR-Reported Primary Outcomes
We conducted logistic regression analyses to evaluate whether study group (SP vs. control) was associated with the three primary outcomes generated via IVR calls. All models were run separately for the acute and maintenance phases. Preliminary analyses indicated no group-related differences in call completion for either unadjusted or adjusted models (both p values≥0.209).
Antidepressant Adherence. Results for the acute phase are shown in Table 2 . We adjusted the model for baseline severity (PHQ-8) and baseline nonadherence (MMAS In contrast, analysis of maintenance-phase data indicated that time neither had a significant main effect (p=0.827) nor did it interact with group (p=0.524). This pattern is apparent in Fig. 1 , which depicts an acute-phase benefit favoring the SP group, and which remained stable during the maintenance phase.
Depression Remission. As can be seen in Table 2 (Model 2), the adjusted odds of achieving remission during the acute phase were lower among patients who had more severe symptoms at baseline (AOR=0.87, 95 % CI: 0.84-0.91, p<0.001). Moreover, group interacted with time (AOR=1.14, 95 % CI: 1.02-1.28, p=0.07), such that patients in the SP group were more likely than controls to achieve remission For the SP group, the od ds of remis sion in cre ase d 2 4% ea ch w eek (AOR=1.24, 95 % CI: 1.14-1.34, p<0.001), but for the control group only 8% per week (AOR=1.08, 95 % CI: 0.999-1.181, p=0.063). During the maintenance phase, neither week nor group X week had a significant effect (p=0.938 and 0.670, respectively). Likewise, the weekly plot of the effects by group (see Fig. 2 ) shows stronger initial improvement in the SP group, followed by good long-term maintenance.
Bed Days due to Depression. The only significant predictor of bed days during the acute phase was baseline symptom severity. Specifically, the odds of having any bed days increased along with baseline severity (AOR=1.10, 95 % CI: 1.06-1.16, p<0.001). Although there was a possible trend for bed days to become less likely over time k (p=0.070), this did not differ by group (p=0.628). Similar to the first two outcome variables, the effects of time and the group X time term were not significant during the maintenance phase (p=0.415 and 0.323, respectively).
DISCUSSION
Although we cannot draw definitive causal conclusions given the non-experimental study design, the results agreed with our prediction that patients who chose to integrate a support person into an mHealth program for management of depression would show greater improvement in adherence and depression symptoms than those who participated in the same program without a support person. It is important to emphasize that these benefits were observed over and above those of a fairly active control condition.
The program consisted of automated weekly IVR calls with clinician feedback. Patients could opt to select a supportive family member or friend who would be automatically sent structured summaries of their IVR calls, along with suggestions for how they could help support patients' self-management. Specifically, for patients who chose to involve a support person, the odds of antidepressant medication adherence during the program's acute phase increased 31% per week (versus 11% for controls), and the odds of depression symptom remission increased 24% per week (versus 8% for controls). Both of these relative advantages were sustained for up to six months. However, the results did not support our hypothesis that the same benefit would occur for functional impairment.
Because adherence to antidepressant medication improves depression outcomes, 20, 21 increased adherence could be one pathway by which extra support may enhance effectiveness. However, symptoms of depression typically require at least 3 to 4 weeks to respond to pharmacotherapy. If this were the only operative mechanism, improvement in symptoms would probably not occur synchronously with-but rather would lag behind-improved adherence (see Fig. 1a and b) .
We therefore believe that regular supportive contact from a trusted and helpful confidant played a role in relieving symptoms independent of medication, perhaps by directly ameliorating the interpersonal isolation and loneliness often experienced by depressed individuals. [7] [8] [9] This interpersonal element Fig. 1 Probability of adherence by group and call-week may have also helped to offset the potentially impersonal and/ or repetitive nature of automated IVR. Although bed days due to depression were not affected in either study group, this is a relatively severe form of impairment that occurred during only about 15% of call-weeks. For patients whose symptoms fall within the mild to moderate range, subtler forms of impairment (e.g., presenteeism, diminished role performance, reduced social functioning) may be more responsive to intensified self-management support. Notwithstanding, functional impairment remains a vitally important behavior to target, given that rigorous trials of behavioral activation indicate that even a few months of better functioning significantly improves the long-term course of depression.
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The primary limitation of this study is its nonexperimental design, specifically that study group assignment was determined by patient preference rather than randomly. As such, we cannot draw definitive conclusions whether intensifying self-management support truly improves mHealth outcomes. A number of unmeasured factors might explain patients' decisions to participate with a support person, including the availability of a willing and capable individual, patient preference for connectedness versus privacy, the need for independence, perceived stigma, social anxiety, and social skills. Our data suggest that it was the more depressed and medically complicated patients who tended to choose this option, which implies that support may appeal to the most vulnerable patients who need it the most. Given that patients who participated with a support person had more severe depression and more comorbid medical conditions prior to program initiation, their relative benefits in adherence and remission are even more striking. While from a traditional trialist perspective, preference designs such as the present one may compromise internal validity, they often enhance ecological realism and external validity due to their closer resemblance to real world clinical care. Moreover, potential confounders that arose from nonrandom assignment may have been mitigated by our statistical adjustment for minority status, medical comorbidity, baseline adherence, and baseline symptom severity.
Another study limitation was our reliance upon selfreporting, although our stringent adherence threshold and brief reporting interval likely offset social desirability and recall biases. 2, 17 In a related issue, disclosure of problems might be inhibited if patients are uncomfortable with the automated interface or believe that denying problems will help abbreviate their IVR calls. Despite the fact that IVR assessment is a wellvalidated method for measuring depression symptoms, 23 follow-up studies should include confirmatory data sources such as electronic medication event monitoring, medical records, and corroboration from significant others. We did not assess adherence to non-pharmacologic therapies (e.g., psychotherapy), nor did we analyze differential effects by specific antidepressant. Although we measured several outcomes from the perspective of patients' support persons, these results will be presented elsewhere. Finally, while the sample was heterogeneous in terms of age, symptom severity, and clinical setting, generalizability may be limited by the preponderance of white women with a post-secondary level of education.
In conclusion, our encouraging preliminary findings suggest that depressed patients' existing social supports are an important but underutilized resource that can be integrated into mHealth interventions to improve antidepressant adherence and mood outcomes. These support persons are presumably motivated to help, but lack the structure and tools needed to do so. If their involvement is amply structured and sufficiently long-term in nature, it may benefit patients clinically while also relieving potentially overextended clinicians and in-home support persons. Our conclusions require confirmation by future research that includes randomized group assignment and multiple data sources. Given the chronic shortages in health care financing and available care management personnel, incorporating patient-designated support persons into automated mHealth programs may help to close the gap between patient needs and the very real limitations inherent in many resource-constrained health care settings.
